CD33 and acute myeloid leukemia: Illustratively, CD33 and CD123, targeted by the conjugate antibody Gemtuzumab Ozogamicin and the fusion protein Tagraxofusp, are also present on normal HSCs [37], while they are expressed in a high but submaximal rate (70–90%) of AML blasts.